Inmaculada Fernandez

Summary

Country: Spain

Publications

  1. ncbi Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis
    Conrado M Fernández-Rodríguez
    Unit of Gastroenterology and Laboratory of Research, Fundacion Hospital Alcorcon, 28922 Madrid, Spain
    Liver Int 24:477-83. 2004
  2. ncbi Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response
    Conrado M Fernández-Rodríguez
    Hospital Universitario Fundacion Alcorcon, Madrid, Spain
    Am J Gastroenterol 105:2164-72; quiz 2173. 2010
  3. ncbi [Treatment optimization in chronic hepatitis C virus infection]
    Conrado M Fernandez Rodriguez
    Servicio de Aparato Digestivo, Hospital Universitario Fundacion Alcorcon, Alcorcon, Madrid, Espana
    Gastroenterol Hepatol 33:119-25. 2010
  4. ncbi Influence of occult hepatitis B virus infection in chronic hepatitis C outcomes
    Conrado M Fernández-Rodríguez
    Service of Gastroenterology, Hospital Universitario Fundacion Alcorcon, University King Juan Carlos, Av Budapest 1, 28922 Alcorcon, Madrid, Spain
    World J Gastroenterol 17:1558-62. 2011
  5. ncbi [Effect of pentoxifylline on survival, cardiac function and both portal and systemic hemodynamics in advanced alcoholic cirrhosis--a randomized double-blind placebo-controlled trial]
    C M Fernandez-Rodriguez
    Unidad de Gastroenterología y Hepatología, Hospital Universitario Fundacion Alcorcon, Avda, Budapest, 1 28922 Alcorcón, Madrid
    Rev Esp Enferm Dig 100:481-9. 2008
  6. ncbi Long-term reversal of hypocholesterolaemia in patients with chronic hepatitis C is related to sustained viral response and viral genotype
    C M Fernandez-Rodriguez
    Units of Gastroenterology and Liver Diseases, Fundación Hospital Alorcón, Madrid, Spain
    Aliment Pharmacol Ther 24:507-12. 2006
  7. ncbi Factors influencing the rate of fibrosis progression in chronic hepatitis C
    Conrado M Fernández-Rodríguez
    Fundacion Hospital Alcorcon, Av Budapest 1, 28922 Madrid, Spain
    Dig Dis Sci 49:1971-6. 2004
  8. ncbi Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C
    Inmaculada Fernandez
    Department of Gastroenterology, Hospital Universitario 12 de Octubre, Madrid, Spain
    Liver Transpl 15:948-55. 2009
  9. ncbi Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation
    Inmaculada Fernandez
    Gastroenterology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
    Liver Transpl 12:1805-12. 2006
  10. ncbi [Association of hyperhomocysteinemia with liver steatosis in patients with chronic hepatitis C]
    Consuelo Fernández-Miranda
    Unidad de Lípidos y Aterosclerosis, Servicio de Medicina Interna, Hospital Universitario 12 de Octubre, Madrid, Espana
    Med Clin (Barc) 136:45-9. 2011

Collaborators

Detail Information

Publications10

  1. ncbi Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis
    Conrado M Fernández-Rodríguez
    Unit of Gastroenterology and Laboratory of Research, Fundacion Hospital Alcorcon, 28922 Madrid, Spain
    Liver Int 24:477-83. 2004
    ..Endocannabinoids may participate in the homeostasis of arterial pressure. Recently, anandamide, the most extensively studied endocannabinoid, has been proposed as a key mediator in the peripheral arterial vasodilation of cirrhosis...
  2. ncbi Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response
    Conrado M Fernández-Rodríguez
    Hospital Universitario Fundacion Alcorcon, Madrid, Spain
    Am J Gastroenterol 105:2164-72; quiz 2173. 2010
    ..Patients with hepatitis C virus (HCV) cirrhosis are difficult to treat and have a high risk of liver decompensation or hepatocellular carcinoma. We sought to identify factors that could predict treatment response...
  3. ncbi [Treatment optimization in chronic hepatitis C virus infection]
    Conrado M Fernandez Rodriguez
    Servicio de Aparato Digestivo, Hospital Universitario Fundacion Alcorcon, Alcorcon, Madrid, Espana
    Gastroenterol Hepatol 33:119-25. 2010
    ..Key factors in treatment optimization are the weight-adjusted dose of ribavirin and therapeutic adherence...
  4. ncbi Influence of occult hepatitis B virus infection in chronic hepatitis C outcomes
    Conrado M Fernández-Rodríguez
    Service of Gastroenterology, Hospital Universitario Fundacion Alcorcon, University King Juan Carlos, Av Budapest 1, 28922 Alcorcon, Madrid, Spain
    World J Gastroenterol 17:1558-62. 2011
    ....
  5. ncbi [Effect of pentoxifylline on survival, cardiac function and both portal and systemic hemodynamics in advanced alcoholic cirrhosis--a randomized double-blind placebo-controlled trial]
    C M Fernandez-Rodriguez
    Unidad de Gastroenterología y Hepatología, Hospital Universitario Fundacion Alcorcon, Avda, Budapest, 1 28922 Alcorcón, Madrid
    Rev Esp Enferm Dig 100:481-9. 2008
    ..To assess the effect of pentoxiphylline (a potent inhibitor of tumor necrosis factor alpha) on survival, on systemic and portal hemodynamics, and on cardiac function in patients with alcoholic cirrhosis...
  6. ncbi Long-term reversal of hypocholesterolaemia in patients with chronic hepatitis C is related to sustained viral response and viral genotype
    C M Fernandez-Rodriguez
    Units of Gastroenterology and Liver Diseases, Fundación Hospital Alorcón, Madrid, Spain
    Aliment Pharmacol Ther 24:507-12. 2006
    ..Genotype-3 of hepatitis C virus (HCV) has been associated with serum lipid changes (reversible with sustained viral response) and liver steatosis...
  7. ncbi Factors influencing the rate of fibrosis progression in chronic hepatitis C
    Conrado M Fernández-Rodríguez
    Fundacion Hospital Alcorcon, Av Budapest 1, 28922 Madrid, Spain
    Dig Dis Sci 49:1971-6. 2004
    ..Combination of these factors did not further accelerate this progression. The impact of modification of these factors on progression should be tested in longitudinal studies...
  8. ncbi Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C
    Inmaculada Fernandez
    Department of Gastroenterology, Hospital Universitario 12 de Octubre, Madrid, Spain
    Liver Transpl 15:948-55. 2009
    ..The use of cyclosporine, ribavirin discontinuation, and viral infection elimination seem to be associated with the development of this complication. Liver Transpl 15:948-955, 2009. (c) 2009 AASLD...
  9. ncbi Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation
    Inmaculada Fernandez
    Gastroenterology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
    Liver Transpl 12:1805-12. 2006
    ..In conclusion, Therapy with PEG-IFN and ribavirin achieved SVR and a significant histological improvement in 23% of liver transplant recipients with chronic hepatitis C. Toxicity is an important drawback of this therapy...
  10. ncbi [Association of hyperhomocysteinemia with liver steatosis in patients with chronic hepatitis C]
    Consuelo Fernández-Miranda
    Unidad de Lípidos y Aterosclerosis, Servicio de Medicina Interna, Hospital Universitario 12 de Octubre, Madrid, Espana
    Med Clin (Barc) 136:45-9. 2011
    ..The aim of this study was to know if hyperhomocysteinemia and methylenetetrahydrofolate reductase (MTHFR)-C677T polymorphisms are associated with liver steatosis in nonalcoholic patients with CHC...